Latest Evommune News & Updates

See the latest news and media coverage for Evommune. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Evommune

Clinical-stage biotechnology company developing therapies for chronic inflammatory diseases

evommune.com
Headquarters
Palo Alto, United States
Founded year
2020
Company type
Private company
Number of employees
50–64

Last updated

Latest news about Evommune

In short: Evommune licensed Hinova’s EVO570 and announced a $30 million private placement.

Company announcements

Evommune

Evommune announces a $30 million private placement

It sells 4,966,889 shares at $6.04 each to healthcare institutional investors, expecting to close around November 6, 2026, and will use the proceeds for clinical programs including EVO570.

Evommune

Evommune reports positive Phase 2a data for EVO301

EVO301 achieved a 55% EASI reduction versus 22% on placebo at Week 12, with a safety profile in line with placebo; a Phase 2b trial is planned for mid-2027.

Unlock all announcements with a

Media coverage

Stock Titan

Evommune halts EVO756 atopic dermatitis program

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points...

Unlock all articles with a

Never miss news about Evommune

Track Evommune and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.